Camp4 Therapeutics CAMP Institutional Ownership

Updated Oct 11, 2026

Camp4 Therapeutics Corp (NASDAQ:CAMP) was reported as a holding by 61 institutional investors in 13F filings for the quarter ended June 30, 2026.

• Collectively, these holders controlled 71.95% of Camp4 Therapeutics' outstanding shares in Q2 2026, up from 68.68% in Q1 2026.
• Total shares held in Camp4 Therapeutics rose 4.77% from Q1 2026, while the number of holders rose 117.86% from Q2 2025.
• Looking at the 61 holders of CAMP individually, 37 added to their positions, 12 reduced their stakes and 12 left their positions unchanged.
• In total, institutional investors held 41.68Mn shares of Camp4 Therapeutics at the end of Q2 2026, up 1.9Mn from the prior quarter and up 29.94Mn from a year earlier.
• Jupiter Topco LLC led 13F holders of CAMP with 6.31Mn shares as of June 30, 2026, or 10.89% of shares outstanding.
• Among existing holders, the largest additions to Camp4 Therapeutics in Q2 2026 came from BlackRock, Inc. (+1.19Mn shares), Geode Capital Management, LLC (+412.83K shares), SummitTX Capital, L.P. (+385.64K shares), State Street Corp (+215.4K shares) and Northern Trust Corp (+178.01K shares).
• Holders that trimmed the most shares of Camp4 Therapeutics in Q2 2026 while keeping a position were Enavate Sciences GP, LLC (-765.38K shares), Balyasny Asset Management L.P. (-56.71K shares), Millennium Management LLC (-42.02K shares), Hudson Bay Capital Management LP (-29.85K shares) and FMR LLC (-29.09K shares).
• Business Quant data shows the 10 biggest positions in Camp4 Therapeutics as of Q2 2026 were held by Jupiter Topco LLC (6.31Mn shares), 5AM Venture Management, LLC (5.87Mn shares), FMR LLC (4.9Mn shares), Vivo Capital, LLC (4.25Mn shares), Balyasny Asset Management L.P. (2.58Mn shares), a16z Capital Management, L.L.C. (2.13Mn shares), Adage Capital Partners GP, L.L.C. (1.96Mn shares), Trails Edge Capital Partners, LP (1.93Mn shares), BlackRock, Inc. (1.64Mn shares) and Vanguard Capital Management LLC (1.53Mn shares).